title: Osteoarthritis in 2016: Anti-NGF treatments for pain - two steps forward, one step back?
authors.affiliation: Center for Musculoskeletal Health, Department of Medicine, University of California at Davis School of Medicine, 4625 2nd Avenue, Sacramento, California 95817, USA.
authors.forename: Nancy E
authors.initials: NE
authors.lastname: Lane
authors.affiliation: Department of Medicine, University of California at San Diego, 9500 Gilman Drive, La Jolla, California 92093-0663, USA.
authors.forename: Maripat
authors.initials: M
authors.lastname: Corr
mesh_terms: D018712:Analgesics, Non-Narcotic / Q000009:adverse effects* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects* / Q000627:therapeutic use; D018771:Arthralgia / Q000188:drug therapy / Q000209:etiology; D059350:Chronic Pain; D006801:Humans; D059352:Musculoskeletal Pain / Q000188:drug therapy* / Q000209:etiology; D020932:Nerve Growth Factor / Q000037:antagonists & inhibitors* / Q000378:metabolism; D010003:Osteoarthritis / Q000150:complications*
chemical_list: D018712:Analgesics, Non-Narcotic; D061067:Antibodies, Monoclonal, Humanized; C000626997:fasinumab; D020932:Nerve Growth Factor; C549319:tanezumab